These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 24215357)

  • 1. A wogonin-loaded glycyrrhetinic acid-modified liposome for hepatic targeting with anti-tumor effects.
    Tian J; Wang L; Wang L; Ke X
    Drug Deliv; 2014 Nov; 21(7):553-9. PubMed ID: 24215357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The anti-tumor performance of docetaxel liposomes surface-modified with glycyrrhetinic acid.
    Li J; Xu H; Ke X; Tian J
    J Drug Target; 2012 Jun; 20(5):467-73. PubMed ID: 22577855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doxorubicin-loaded glycyrrhetinic acid modified recombinant human serum albumin nanoparticles for targeting liver tumor chemotherapy.
    Qi WW; Yu HY; Guo H; Lou J; Wang ZM; Liu P; Sapin-Minet A; Maincent P; Hong XC; Hu XM; Xiao YL
    Mol Pharm; 2015 Mar; 12(3):675-83. PubMed ID: 25584860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumor therapy of glycyrrhetinic acid targeted liposome co-delivery of doxorubicin and berberine for hepatocellular carcinoma.
    Xu N; Wu J; Wang W; Sun S; Sun M; Bian Y; Zhang H; Liu S; Yu G
    Drug Deliv Transl Res; 2024 Sep; 14(9):2386-2402. PubMed ID: 38236508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of Salvianolic acid B-Tanshinone II A-Glycyrrhetinic acid compound liposomes: formulation optimization and its effects on proliferation of hepatic stellate cells.
    Lin J; Wang X; Wu Q; Dai J; Guan H; Cao W; He L; Wang Y
    Int J Pharm; 2014 Feb; 462(1-2):11-8. PubMed ID: 24374609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular uptake mechanism and clearance kinetics of fluorescence-labeled glycyrrhetinic acid and glycyrrhetinic acid-modified liposome in hepatocellular carcinoma cells.
    Sun Y; Lu J; Yan D; Shen L; Hu H; Chen D
    Environ Toxicol Pharmacol; 2017 Jul; 53():46-56. PubMed ID: 28501784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycyrrhetinic Acid and TAT Peptide Modified Dual-functional Liposomes for Treatment of Hepatocellular Cancer.
    Huang S; Ren D; Wu X; Li M; Yu X; Nie X; Wang Y; Wang Y
    Curr Top Med Chem; 2020; 20(27):2493-2505. PubMed ID: 32703132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activities of novel glycyrrhetinic acid-modified curcumin-loaded cationic liposomes in vitro and in H22 tumor-bearing mice.
    Chang M; Wu M; Li H
    Drug Deliv; 2018 Nov; 25(1):1984-1995. PubMed ID: 30499350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual-Ligand-Functionalized Liposomes Based on Glycyrrhetinic Acid and cRGD for Hepatocellular Carcinoma Targeting and Therapy.
    Qiu M; Wang J; Bai J; Li X; Tian C; Liu Z; Zheng C; Clark AR; Cheng X; Liao X; Wu S; Lee RJ; Zhou X
    Mol Pharm; 2023 Apr; 20(4):1951-1963. PubMed ID: 36952242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Preparation of liposomes surface-modified with glycyrrhetinic acid targeting to hepatocytes].
    Mao SJ; Hou SX; Jin H; Zhang LK; Jiang-Bin
    Zhongguo Zhong Yao Za Zhi; 2003 Apr; 28(4):328-31. PubMed ID: 15139140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of 11-DGA-3-
    Zhou L; Zou M; Zhu K; Ning S; Xia X
    Molecules; 2019 Aug; 24(17):. PubMed ID: 31450608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18-GA-Suc Modified Liposome Loading Cantharidin for Augmenting Hepatic Specificity: Preparation, Characterization, Antitumor Effects, and Liver-Targeting Efficiency.
    Zhu K; Zhou L; Zou M; Ning S; Liu S; Zhou Y; Du K; Zhang X; Xia X
    J Pharm Sci; 2020 Jun; 109(6):2038-2047. PubMed ID: 32173319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocellular carcinoma-targeted effect of configurations and groups of glycyrrhetinic acid by evaluation of its derivative-modified liposomes.
    Sun Y; Dai C; Yin M; Lu J; Hu H; Chen D
    Int J Nanomedicine; 2018; 13():1621-1632. PubMed ID: 29588589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced distribution and extended elimination of glycyrrhetinic acid in mice liver by mPEG-PLA modified (mPEGylated) liposome.
    Li J; Yu H; Li S; Wang GJ
    J Pharm Biomed Anal; 2010 Apr; 51(5):1147-53. PubMed ID: 20005656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycyrrhetinic acid-graft-hyaluronic acid conjugate as a carrier for synergistic targeted delivery of antitumor drugs.
    Zhang L; Yao J; Zhou J; Wang T; Zhang Q
    Int J Pharm; 2013 Jan; 441(1-2):654-64. PubMed ID: 23117024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HPLC assay and pharmacokinetics and tissue distribution study of glycyrrhetinic acid liposomes modified with galactosylated lipid.
    Guo BH; Cheng Y; Wu W; Lin LP; Lin DH
    J Liposome Res; 2012 Jun; 22(2):120-7. PubMed ID: 22313057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced targeted delivery of adenine to hepatocellular carcinoma using glycyrrhetinic acid-functionalized nanoparticles in vivo and in vitro.
    Wu F; Xue H; Li X; Diao W; Jiang B; Wang W; Yu W; Bai J; Wang Y; Lian B; Feng W; Sun T; Qu M; Zhao C; Wang Y; Wu J; Gao Z
    Biomed Pharmacother; 2020 Nov; 131():110682. PubMed ID: 32947204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycyrrhetinic Acid Mediated Drug Delivery Carriers for Hepatocellular Carcinoma Therapy.
    Cai Y; Xu Y; Chan HF; Fang X; He C; Chen M
    Mol Pharm; 2016 Mar; 13(3):699-709. PubMed ID: 26808002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of glycyrrhetinic acid-modified stealth cationic liposomes for gene delivery.
    He ZY; Zheng X; Wu XH; Song XR; He G; Wu WF; Yu S; Mao SJ; Wei YQ
    Int J Pharm; 2010 Sep; 397(1-2):147-54. PubMed ID: 20667672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Liver targeting of compound liposomes mediated by glycyrrhetinic acid derivative receptor and its effect on hepatic stellate cells].
    Wang XL; Guan HD; Qu SX; Xue BW; Li G; Liu XY; Chen LS; Gu H
    Zhongguo Zhong Yao Za Zhi; 2023 Oct; 48(19):5195-5204. PubMed ID: 38114109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.